{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,12]],"date-time":"2025-09-12T17:54:52Z","timestamp":1757699692738},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2010,3,4]],"date-time":"2010-03-04T00:00:00Z","timestamp":1267660800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Graefes Arch Clin Exp Ophthalmol"],"published-print":{"date-parts":[[2010,7]]},"DOI":"10.1007\/s00417-009-1256-6","type":"journal-article","created":{"date-parts":[[2010,3,3]],"date-time":"2010-03-03T20:22:10Z","timestamp":1267647730000},"page":"943-956","source":"Crossref","is-referenced-by-count":21,"title":["Treatment of neovascular age-related macular degeneration with a variable ranibizumab dosing regimen and one-time reduced-fluence photodynamic therapy: the TORPEDO trial at 2\u00a0years"],"prefix":"10.1007","volume":"248","author":[{"given":"Leigh","family":"Spielberg","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anita","family":"Leys","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2010,3,4]]},"reference":[{"key":"1256_CR1","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1001\/archopht.122.4.598","volume":"122","author":"MA Zarbin","year":"2004","unstructured":"Zarbin MA (2004) Current concepts in the pathogenesis of age-related macular degeneration. Arch Ophthalmol 122:598\u2013614. doi: 10.1001\/archopht.122.4.598 122\/4\/598 [pii]","journal-title":"Arch Ophthalmol"},{"key":"1256_CR2","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1016\/j.ajo.2007.08.012","volume":"144","author":"PK Kaiser","year":"2007","unstructured":"Kaiser PK, Brown DM, Zhang K, Hudson HL, Holz FG, Shapiro H, Schneider S, Acharya NR (2007) Ranibizumab for predominantly classic neovascular age-related macular degeneration: subgroup analysis of first-year ANCHOR results. Am J Ophthalmol 144:850\u2013857. doi: S0002-9394(07)00718-0 [pii] 10.1016\/j.ajo.2007.08.012","journal-title":"Am J Ophthalmol"},{"key":"1256_CR3","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.ophtha.2008.10.018","volume":"116","author":"DM Brown","year":"2009","unstructured":"Brown DM, Michels M, Kaiser PK, Heier JS, Sy JP, Ianchulev T (2009) Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: two-year results of the ANCHOR study. Ophthalmology 116:57\u201365 e55. doi: S0161-6420(08)01075-0 [pii] 10.1016\/j.ophtha.2008.10.018","journal-title":"Ophthalmology"},{"key":"1256_CR4","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1001\/archopht.124.11.1532","volume":"124","author":"JS Heier","year":"2006","unstructured":"Heier JS, Boyer DS, Ciulla TA, Ferrone PJ, Jumper JM, Gentile RC, Kotlovker D, Chung CY, Kim RY (2006) Ranibizumab combined with verteporfin photodynamic therapy in neovascular age-related macular degeneration: year 1 results of the FOCUS Study. Arch Ophthalmol 124:1532\u20131542. doi: 124\/11\/1532 [pii] 10.1001\/archopht.124.11.1532","journal-title":"Arch Ophthalmol"},{"key":"1256_CR5","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1136\/bjo.2007.135277","volume":"92","author":"U Schmidt-Erfurth","year":"2008","unstructured":"Schmidt-Erfurth U, Wolf S (2008) Same-day administration of verteporfin and ranibizumab 0.5\u00a0mg in patients with choroidal neovascularisation due to age-related macular degeneration. Br J Ophthalmol 92:1628\u20131635. doi: bjo.2007.135277 [pii] 10.1136\/bjo.2007.135277","journal-title":"Br J Ophthalmol"},{"key":"1256_CR6","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.ajo.2008.08.018","volume":"147","author":"DF Kiernan","year":"2009","unstructured":"Kiernan DF, Hariprasad SM, Chin EK, Kiernan CL, Rago J, Mieler WF (2009) Prospective comparison of Cirrus and Stratus optical coherence tomography for quantifying retinal thickness. Am J Ophthalmol 147:267\u2013275 e262. doi: S0002-9394(08)00661-2 [pii] 10.1016\/j.ajo.2008.08.018","journal-title":"Am J Ophthalmol"},{"key":"1256_CR7","author":"P Carpineto","year":"2009","unstructured":"Carpineto P, Nubile M, Toto L, Aharrh Gnama A, Marcucci L, Mastropasqua L, Ciancaglini M (2009) Correlation in foveal thickness measurements between spectral-domain and time-domain optical coherence tomography in normal individuals. Eye. doi: eye200976 [pii] 10.1038\/eye.2009.76","journal-title":"Eye"},{"key":"1256_CR8","author":"C Cukras","year":"2009","unstructured":"Cukras C, Wang YD, Meyerle CB, Forooghian F, Chew EY, Wong WT (2009) Optical coherence tomography-based decision making in exudative age-related macular degeneration: comparison of time- vs spectral-domain devices. Eye. doi: eye2009211 [pii] 10.1038\/eye.2009.211","journal-title":"Eye"},{"key":"1256_CR9","unstructured":"Durbin M AT, Chang M, Lujan B (2009) Retinal measurements: comparison between Cirrus HD-OCT and Stratus OCT. Zeiss-Meditec White Paper"},{"key":"1256_CR10","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1056\/NEJMoa054481","volume":"355","author":"PJ Rosenfeld","year":"2006","unstructured":"Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY, Kim RY (2006) Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 355:1419\u20131431. doi: 355\/14\/1419 [pii] 10.1056\/NEJMoa054481","journal-title":"N Engl J Med"},{"key":"1256_CR11","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1056\/NEJMoa062655","volume":"355","author":"DM Brown","year":"2006","unstructured":"Brown DM, Kaiser PK, Michels M, Soubrane G, Heier JS, Kim RY, Sy JP, Schneider S (2006) Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 355:1432\u20131444. doi: 355\/14\/1432 [pii] 10.1056\/NEJMoa062655","journal-title":"N Engl J Med"},{"key":"1256_CR12","doi-asserted-by":"crossref","first-page":"53","DOI":"10.2353\/ajpath.2007.061237","volume":"171","author":"K Nishijima","year":"2007","unstructured":"Nishijima K, Ng YS, Zhong L, Bradley J, Schubert W, Jo N, Akita J, Samuelsson SJ, Robinson GS, Adamis AP, Shima DT (2007) Vascular endothelial growth factor-A is a survival factor for retinal neurons and a critical neuroprotectant during the adaptive response to ischemic injury. Am J Pathol 171:53\u201367. doi: 171\/1\/53 [pii]","journal-title":"Am J Pathol"},{"key":"1256_CR13","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/s00417-003-0828-0","volume":"242","author":"RO Schlingemann","year":"2004","unstructured":"Schlingemann RO (2004) Role of growth factors and the wound healing response in age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol 242:91\u2013101. doi: 10.1007\/s00417-003-0828-0","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"1256_CR14","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.ajo.2007.10.004","volume":"145","author":"CD Regillo","year":"2008","unstructured":"Regillo CD, Brown DM, Abraham P, Yue H, Ianchulev T, Schneider S, Shams N (2008) Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER Study year 1. Am J Ophthalmol 145:239\u2013248. doi: S0002-9394(07)00881-1 [pii] 10.1016\/j.ajo.2007.10.004","journal-title":"Am J Ophthalmol"},{"key":"1256_CR15","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1016\/j.ajo.2007.01.028","volume":"143","author":"AE Fung","year":"2007","unstructured":"Fung AE, Lalwani GA, Rosenfeld PJ, Dubovy SR, Michels S, Feuer WJ, Puliafito CA, Davis JL, Flynn HW Jr, Esquiabro M (2007) An optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration. Am J Ophthalmol 143:566\u2013583. doi: S0002-9394(07)00068-2 [pii] 10.1016\/j.ajo.2007.01.028","journal-title":"Am J Ophthalmol"},{"key":"1256_CR16","author":"FG Holz","year":"2009","unstructured":"Holz FG, Korobelnik JF, Lanzetta P, Mitchell P, Schmidt-Erfurth U, Wolf S, Markabi S, Schmidli H, Weichselberger A (2009) The effects of a flexible visual acuity-driven ranibizumab treatment regimen in age-related macular degeneration: outcomes of a drug and disease model. Invest Ophthalmol Vis Sci. doi: iovs.09-3813 [pii] 10.1167\/iovs.09-3813","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"1256_CR17","first-page":"361","volume":"19","author":"PJ Rosenfeld","year":"2006","unstructured":"Rosenfeld PJ, Rich RM, Lalwani GA (2006) Ranibizumab: phase III clinical trial results. Ophthalmol Clin North Am 19:361\u2013372. doi: S0896-1549(06)00054-X [pii] 10.1016\/j.ohc.2006.05.009","journal-title":"Ophthalmol Clin North Am"},{"key":"1256_CR18","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/j.ajo.2007.02.024","volume":"143","author":"R Spaide","year":"2007","unstructured":"Spaide R (2007) Ranibizumab according to need: a treatment for age-related macular degeneration. Am J Ophthalmol 143:679\u2013680. doi: S0002-9394(07)00190-0 [pii] 10.1016\/j.ajo.2007.02.024","journal-title":"Am J Ophthalmol"},{"key":"1256_CR19","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1136\/bjo.2006.109702","volume":"91","author":"S Peters","year":"2007","unstructured":"Peters S, Julien S, Heiduschka P, Grisanti S, Ziemssen F, Adler M, Schraermeyer U, Bartz-Schmidt KU (2007) Antipermeability and antiproliferative effects of standard and frozen bevacizumab on choroidal endothelial cells. Br J Ophthalmol 91:827\u2013831. doi: bjo.2006.109702 [pii] 10.1136\/bjo.2006.109702","journal-title":"Br J Ophthalmol"},{"key":"1256_CR20","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1007\/s00347-006-1356-1","volume":"103","author":"M Volcker","year":"2006","unstructured":"Volcker M, Peters S, Inhoffen W, Ziemssen F (2006) Early antiexudative response-OCT monitoring after intravitreal bevacizumab injection. Ophthalmologe 103:476\u2013483. doi: 10.1007\/s00347-006-1356-1","journal-title":"Ophthalmologe"},{"key":"1256_CR21","doi-asserted-by":"crossref","first-page":"331","DOI":"10.3928\/1542-8877-20050701-14","volume":"36","author":"PJ Rosenfeld","year":"2005","unstructured":"Rosenfeld PJ, Moshfeghi AA, Puliafito CA (2005) Optical coherence tomography findings after an intravitreal injection of bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmic Surg Lasers Imaging 36:331\u2013335","journal-title":"Ophthalmic Surg Lasers Imaging"},{"key":"1256_CR22","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.ajo.2007.09.031","volume":"145","author":"ZF Bashshur","year":"2008","unstructured":"Bashshur ZF, Haddad ZA, Schakal A, Jaafar RF, Saab M, Noureddin BN (2008) Intravitreal bevacizumab for treatment of neovascular age-related macular degeneration: a one-year prospective study. Am J Ophthalmol 145:249\u2013256. doi: S0002-9394(07)00854-9 [pii] 10.1016\/j.ajo.2007.09.031","journal-title":"Am J Ophthalmol"},{"key":"1256_CR23","doi-asserted-by":"crossref","first-page":"1868","DOI":"10.1016\/j.ophtha.2007.04.030","volume":"114","author":"PK Kaiser","year":"2007","unstructured":"Kaiser PK, Blodi BA, Shapiro H, Acharya NR (2007) Angiographic and optical coherence tomographic results of the MARINA study of ranibizumab in neovascular age-related macular degeneration. Ophthalmology 114:1868\u20131875. doi: S0161-6420(07)00467-8 [pii] 10.1016\/j.ophtha.2007.04.030","journal-title":"Ophthalmology"},{"key":"1256_CR24","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/s10456-007-9069-x","volume":"10","author":"J Bradley","year":"2007","unstructured":"Bradley J, Ju M, Robinson GS (2007) Combination therapy for the treatment of ocular neovascularization. Angiogenesis 10:141\u2013148. doi: 10.1007\/s10456-007-9069-x","journal-title":"Angiogenesis"},{"key":"1256_CR25","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1172\/JCI200317929","volume":"111","author":"G Bergers","year":"2003","unstructured":"Bergers G, Song S, Meyer-Morse N, Bergsland E, Hanahan D (2003) Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors. J Clin Invest 111:1287\u20131295. doi: 10.1172\/JCI17929","journal-title":"J Clin Invest"},{"key":"1256_CR26","doi-asserted-by":"crossref","first-page":"2036","DOI":"10.2353\/ajpath.2006.050588","volume":"168","author":"N Jo","year":"2006","unstructured":"Jo N, Mailhos C, Ju M, Cheung E, Bradley J, Nishijima K, Robinson GS, Adamis AP, Shima DT (2006) Inhibition of platelet-derived growth factor B signaling enhances the efficacy of anti-vascular endothelial growth factor therapy in multiple models of ocular neovascularization. Am J Pathol 168:2036\u20132053. doi: 168\/6\/2036 [pii]","journal-title":"Am J Pathol"},{"key":"1256_CR27","first-page":"3974","volume":"35","author":"PA D\u2019Amore","year":"1994","unstructured":"D\u2019Amore PA (1994) Mechanisms of retinal and choroidal neovascularization. Invest Ophthalmol Vis Sci 35:3974\u20133979","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"1256_CR28","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/S0002-9394(14)70868-2","volume":"124","author":"R Casey","year":"1997","unstructured":"Casey R, Li WW (1997) Factors controlling ocular angiogenesis. Am J Ophthalmol 124:521\u2013529","journal-title":"Am J Ophthalmol"},{"key":"1256_CR29","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1016\/j.preteyeres.2003.08.001","volume":"22","author":"A Das","year":"2003","unstructured":"Das A, McGuire PG (2003) Retinal and choroidal angiogenesis: pathophysiology and strategies for inhibition. Prog Retin Eye Res 22:721\u2013748. doi: S135094620300065X [pii]","journal-title":"Prog Retin Eye Res"},{"key":"1256_CR30","doi-asserted-by":"crossref","first-page":"979","DOI":"10.2165\/00002512-200724120-00002","volume":"24","author":"A Augustin","year":"2007","unstructured":"Augustin A, Offerman I (2007) Combination therapy for choroidal neovascularisation. Drugs Aging 24:979\u2013990","journal-title":"Drugs Aging"},{"key":"1256_CR31","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1111\/j.1755-3768.2007.00979.x","volume":"85","author":"UM Schmidt-Erfurth","year":"2007","unstructured":"Schmidt-Erfurth UM, Richard G, Augustin A, Aylward WG, Bandello F, Corcostegui B, Cunha-Vaz J, Gaudric A, Leys A, Schlingemann RO (2007) Guidance for the treatment of neovascular age-related macular degeneration. Acta Ophthalmol Scand 85:486\u2013494. doi: AOS979 [pii] 10.1111\/j.1600-0420.2007.00979.x","journal-title":"Acta Ophthalmol Scand"},{"key":"1256_CR32","doi-asserted-by":"crossref","first-page":"2147","DOI":"10.1167\/iovs.02-0604","volume":"44","author":"S Michels","year":"2003","unstructured":"Michels S, Schmidt-Erfurth U (2003) Sequence of early vascular events after photodynamic therapy. Invest Ophthalmol Vis Sci 44:2147\u20132154","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"1256_CR33","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1007\/s00417-005-0199-9","volume":"244","author":"PK Kaiser","year":"2006","unstructured":"Kaiser PK (2006) Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: 5-year results of two randomized clinical trials with an open-label extension: TAP report no. 8. Graefes Arch Clin Exp Ophthalmol 244:1132\u20131142. doi: 10.1007\/s00417-005-0199-9","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"1256_CR34","doi-asserted-by":"crossref","first-page":"4473","DOI":"10.1167\/iovs.02-1115","volume":"44","author":"U Schmidt-Erfurth","year":"2003","unstructured":"Schmidt-Erfurth U, Schlotzer-Schrehard U, Cursiefen C, Michels S, Beckendorf A, Naumann GO (2003) Influence of photodynamic therapy on expression of vascular endothelial growth factor (VEGF), VEGF receptor 3, and pigment epithelium-derived factor. Invest Ophthalmol Vis Sci 44:4473\u20134480","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"1256_CR35","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1016\/j.ajo.2007.12.029","volume":"145","author":"AN Antoszyk","year":"2008","unstructured":"Antoszyk AN, Tuomi L, Chung CY, Singh A (2008) Ranibizumab combined with verteporfin photodynamic therapy in neovascular age-related macular degeneration (FOCUS): year 2 results. Am J Ophthalmol 145:862\u2013874. doi: S0002-9394(08)00008-1 [pii] 10.1016\/j.ajo.2007.12.029","journal-title":"Am J Ophthalmol"},{"key":"1256_CR36","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1001\/archopht.123.4.509","volume":"123","author":"D Husain","year":"2005","unstructured":"Husain D, Kim I, Gauthier D, Lane AM, Tsilimbaris MK, Ezra E, Connolly EJ, Michaud N, Gragoudas ES, O\u2019Neill CA, Beyer JC, Miller JW (2005) Safety and efficacy of intravitreal injection of ranibizumab in combination with verteporfin PDT on experimental choroidal neovascularization in the monkey. Arch Ophthalmol 123:509\u2013516. doi: 123\/4\/509 [pii] 10.1001\/archopht.123.4.509","journal-title":"Arch Ophthalmol"},{"key":"1256_CR37","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1001\/archopht.123.4.448","volume":"123","author":"M Azab","year":"2005","unstructured":"Azab M, Boyer DS, Bressler NM, Bressler SB, Cihelkova I, Hao Y, Immonen I, Lim JI, Menchini U, Naor J, Potter MJ, Reaves A, Rosenfeld PJ, Slakter JS, Soucek P, Strong HA, Wenkstern A, Su XY, Yang YC (2005) Verteporfin therapy of subfoveal minimally classic choroidal neovascularization in age-related macular degeneration: 2-year results of a randomized clinical trial. Arch Ophthalmol 123:448\u2013457. doi: 123\/4\/448 [pii] 10.1001\/archopht.123.4.448","journal-title":"Arch Ophthalmol"},{"key":"1256_CR38","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1097\/IAE.0b013e31817082d7","volume":"28","author":"CN Singh","year":"2008","unstructured":"Singh CN, Saperstein DA (2008) Combination treatment with reduced-fluence photodynamic therapy and intravitreal injection of triamcinolone for subfoveal choroidal neovascularization in macular degeneration. Retina 28:789\u2013793. doi: 10.1097\/IAE.0b013e31817082d7 00006982-200806000-00001 [pii]","journal-title":"Retina"},{"key":"1256_CR39","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/S0161-6420(96)30675-1","volume":"103","author":"M Kramer","year":"1996","unstructured":"Kramer M, Miller JW, Michaud N, Moulton RS, Hasan T, Flotte TJ, Gragoudas ES (1996) Liposomal benzoporphyrin derivative verteporfin photodynamic therapy. Selective treatment of choroidal neovascularization in monkeys. Ophthalmology 103:427\u2013438","journal-title":"Ophthalmology"},{"key":"1256_CR40","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1001\/archopht.117.9.1161","volume":"117","author":"JW Miller","year":"1999","unstructured":"Miller JW, Schmidt-Erfurth U, Sickenberg M, Pournaras CJ, Laqua H, Barbazetto I, Zografos L, Piguet B, Donati G, Lane AM, Birngruber R, van den Berg H, Strong A, Manjuris U, Gray T, Fsadni M, Bressler NM, Gragoudas ES (1999) Photodynamic therapy with verteporfin for choroidal neovascularization caused by age-related macular degeneration: results of a single treatment in a phase 1 and 2 study. Arch Ophthalmol 117:1161\u20131173","journal-title":"Arch Ophthalmol"},{"key":"1256_CR41","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1167\/iovs.05-0354","volume":"47","author":"S Michels","year":"2006","unstructured":"Michels S, Hansmann F, Geitzenauer W, Schmidt-Erfurth U (2006) Influence of treatment parameters on selectivity of verteporfin therapy. Invest Ophthalmol Vis Sci 47:371\u2013376. doi: 47\/1\/371 [pii] 10.1167\/iovs.05-0354","journal-title":"Invest Ophthalmol Vis Sci"}],"container-title":["Graefe's Archive for Clinical and Experimental Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00417-009-1256-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00417-009-1256-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00417-009-1256-6","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,28]],"date-time":"2019-05-28T19:40:51Z","timestamp":1559072451000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00417-009-1256-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,3,4]]},"references-count":41,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2010,7]]}},"alternative-id":["1256"],"URL":"https:\/\/doi.org\/10.1007\/s00417-009-1256-6","relation":{},"ISSN":["0721-832X","1435-702X"],"issn-type":[{"value":"0721-832X","type":"print"},{"value":"1435-702X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,3,4]]}}}